| Q61798472 | 5-HT2 receptor binding, functional activity and selectivity in N-benzyltryptamines |
| Q37789738 | 5-HT2C receptor modulators: a patent survey |
| Q36244665 | Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice |
| Q37960073 | Approaches to the pharmacological treatment of obesity |
| Q50966630 | Asymmetric synthesis of 3-substituted tetrahydro-2-benzazepines. |
| Q88342804 | Bioassay-guided isolation of saikosaponins with agonistic activity on 5-hydroxytryptamine 2C receptor from Bupleurum chinense and their potential use for the treatment of obesity |
| Q58764917 | Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release |
| Q58867083 | Chapter 7: Seven-Membered Rings |
| Q35049574 | Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity |
| Q50227324 | Choice between delayed food and immediate opioids in rats: treatment effects and individual differences |
| Q30672639 | Conformational analysis of the anti-obesity drug lorcaserin in water: how to take advantage of long-range residual dipolar couplings |
| Q52645818 | Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist. |
| Q34462524 | Directed evolution of RebH for site-selective halogenation of large biologically active molecules |
| Q36316458 | Directly Observable Behavioral Effects of Lorcaserin in Rats |
| Q39768889 | Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? |
| Q53642036 | Distinguishing rotamers in N-trifluoroacetyl-3-benzazepine derivatives. |
| Q64063235 | Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies |
| Q33838889 | Effects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model |
| Q34207033 | Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification |
| Q34212924 | High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes |
| Q47172455 | Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating. |
| Q38031743 | Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. |
| Q46213450 | Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women |
| Q37310802 | Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity |
| Q36432310 | Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys |
| Q48013285 | Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists |
| Q34659424 | Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease |
| Q38385068 | Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial |
| Q37172259 | Lorcaserin for the treatment of obesity |
| Q42957301 | Lorcaserin for the treatment of obesity? A closer look at its side effects |
| Q24611940 | Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure |
| Q35188133 | Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats |
| Q37947448 | Lorcaserin: an investigational serotonin 2C agonist for weight loss |
| Q26749523 | Mechanistic relationship between the vagal afferent pathway, central nervous system and peripheral organs in appetite regulation |
| Q37660087 | New therapeutic potential for psychoactive natural products |
| Q26828559 | Obesity pharmacotherapy: current perspectives and future directions |
| Q39298178 | Pharmacologic activation of estrogen receptor β increases mitochondrial function, energy expenditure, and brown adipose tissue |
| Q60305402 | Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats |
| Q53714273 | Potential functional and pathological side effects related to off-target pharmacological activity. |
| Q53251686 | Regioselective alkylation of 1,3,4,5-tetrahydrobenzo[d]azepin-2-one and biological evaluation of the resulting alkylated products as potentially selective [Formula: see text] agonists. |
| Q45908028 | Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist. |
| Q47588598 | Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists |
| Q38954263 | Safety and tolerability review of lorcaserin in clinical trials. |
| Q34962263 | Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action |
| Q27676926 | Structural Basis for Molecular Recognition at Serotonin Receptors |
| Q36540945 | Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction |
| Q36777115 | Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism |
| Q51076938 | Synthesis, σ receptor affinity, and pharmacological evaluation of 5-phenylsulfanyl- and 5-benzyl-substituted tetrahydro-2-benzazepines. |
| Q35837700 | The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control |
| Q41910031 | The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. |
| Q38160636 | The safety and efficacy of lorcaserin in the management of obesity |
| Q24594774 | The use of lorcaserin in the management of obesity: a critical appraisal |
| Q34712327 | The use of serotonergic drugs to treat obesity--is there any hope? |
| Q35589958 | The utility of animal models to evaluate novel anti-obesity agents |
| Q55259526 | Understanding and Improving the Activity of Flavin-Dependent Halogenases via Random and Targeted Mutagenesis. |
| Q35823591 | We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. |